Hong Kong
· Delayed Price · Currency is HKD Clover Biopharmaceuticals Statistics
Total Valuation
HKG:2197 has a market cap or net worth of HKD 271.09 million. The enterprise value is -76.24 million.
| Market Cap | 271.09M |
| Enterprise Value | -76.24M |
Important Dates
The next estimated earnings date is Tuesday, May 27, 2025.
| Earnings Date | May 27, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
HKG:2197 has 1.30 billion shares outstanding. The number of shares has increased by 0.82% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 1.30B |
| Shares Change (YoY) | +0.82% |
| Shares Change (QoQ) | +0.28% |
| Owned by Insiders (%) | 20.32% |
| Owned by Institutions (%) | 8.96% |
| Float | 741.55M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 6.63 |
| PB Ratio | -0.16 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 0.08 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 0.25 |
Financial Position
The company has a current ratio of 0.35
| Current Ratio | 0.35 |
| Quick Ratio | 0.25 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.31 |
| Interest Coverage | -165.89 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -40.96% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | 87.21% |
| Revenue Per Employee | 136,281 |
| Profits Per Employee | -3.20M |
| Employee Count | 387 |
| Asset Turnover | 0.03 |
| Inventory Turnover | 2.01 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -34.69% in the last 52 weeks. The beta is 3.60, so HKG:2197's price volatility has been higher than the market average.
| Beta (5Y) | 3.60 |
| 52-Week Price Change | -34.69% |
| 50-Day Moving Average | 0.27 |
| 200-Day Moving Average | 0.28 |
| Relative Strength Index (RSI) | 39.12 |
| Average Volume (20 Days) | 1,250,904 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, HKG:2197 had revenue of HKD 40.88 million and -961.40 million in losses. Loss per share was -0.77.
| Revenue | 40.88M |
| Gross Profit | -716.13M |
| Operating Income | -1.02B |
| Pretax Income | -961.40M |
| Net Income | -961.40M |
| EBITDA | -985.89M |
| EBIT | -1.02B |
| Loss Per Share | -0.77 |
Balance Sheet
The company has 442.72 million in cash and 95.40 million in debt, giving a net cash position of 347.32 million or 0.27 per share.
| Cash & Cash Equivalents | 442.72M |
| Total Debt | 95.40M |
| Net Cash | 347.32M |
| Net Cash Per Share | 0.27 |
| Equity (Book Value) | -1.74B |
| Book Value Per Share | -1.34 |
| Working Capital | -1.32B |
Cash Flow
In the last 12 months, operating cash flow was -307.00 million and capital expenditures -1.21 million, giving a free cash flow of -308.20 million.
| Operating Cash Flow | -307.00M |
| Capital Expenditures | -1.21M |
| Free Cash Flow | -308.20M |
| FCF Per Share | -0.24 |
Margins
| Gross Margin | n/a |
| Operating Margin | -2,485.33% |
| Pretax Margin | -2,351.51% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
HKG:2197 does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.82% |
| Shareholder Yield | -0.82% |
| Earnings Yield | -354.65% |
| FCF Yield | -113.69% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
HKG:2197 has an Altman Z-Score of -23.73. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -23.73 |
| Piotroski F-Score | n/a |